© ChromaCon 2016



# N-Rich<sup>®</sup>: A tool for efficient isolation of minor compounds from complex matrices





#### Outlook

**N-Rich<sup>®</sup>** has a wide range of applications, including:

rapid isolation of product-related compounds for pre-clinical research, stability and formulation studies

- Monoclonal antibody isoforms
- Antibody conjugates
- Biosimilar isoforms
- Blood plasma proteins
- Other API, natural products
- preparation of analytical standards
- mining and isolation of natural products with therapeutic potential
- mining of biomarkers, proteomes or metabolomes:

as general sample preparation tool with MS/MS detection

isolation of therapeutic targets for development of bioassays



#### **N-Rich Introduction**

- N-Rich is a powerful preparative chromatographic periodic countercurrent process allowing to enrich minor components from complex mixtures and at the same time deplete major components of the mixture that may interfere in the isolation of the minor component of interest
- N-Rich achieves unparalleled enrichment and separation capabilities only comparable to high resolution analytical HPLC but with the advantage of isolating preparative amounts of compounds within a short time
- A twin-column HPLC/FPLC system configuration (Contichrom<sup>®</sup>) allows to run N-Rich efficiently
- Conventional resin material such as IEX, HIC, RP-C8, etc. can be used. No need for any type of specific affinity step or pre-fractionation
- N-Rich applications can be grouped for:
  - ✓ Isolation of product-related impurities for pre-clinical research, stability studies and formulation studies (when the product is known)
  - ✓ Discovery applications: screening for biomarkers, of proteomes or metabolomes (when the compounds of interest are not yet known)



## Use of N-Rich for Isolation of Protein Isoforms

- Regulatory requirements (ICH Q6B and ICH Q3A (R2) guidelines) require the isolation and characterization of product-related impurities
- Follow-on biologics (Biosimilars) need to be as close as possible to their originator product in order to be eligible for biosimilarity and for product interchangeability claims. The analytical identity to a standard is an important starting point
- Biological products contain isoforms, based on post-translational events, ageing and stress. Those isoforms may change the safety and efficacy profile and they therefore need to be isolated and characterized.
- Isoforms being closely related to the product are difficult to isolate in substantial amounts for the required characterization assays
- Repetitive analytical injections (several hundred) are frequently used to isolate product-related impurities. The process is tedious and may stress the isolated impurity during the isolation process



### Use of N-Rich for Isolation of Protein Isoforms (cont'd)

- A long impurity isolation process may change the nature of the impurity itself during the isolation process, making the isolated impurity non-representative
- N-Rich is a twin-column chromatography process providing highly enriched material from complex samples without the use of any specific resin material
  - ✓ in a short period of time (overnight)
  - $\checkmark$  automatically with minimal handling effort



#### **N-Rich for Biosimilars**

- A biosimilar has to be defined stringently as a product that is very similar to an originator product
- Analytical similarity data is the foundation of biosimilar development understanding the relationship between quality attributes and the clinical safety & efficacy profile aids to determine residual uncertainty about biosimilarity and to predict expected "clinical similarity" from the biosimilar product quality data.
- Biosimilarity is thus defined initially through the product composition compared to a standard and only later confirmed through safety data
- Separation of the product composition is the main task before product component characterization and comparison to the originator product
- ChromaCon has used N-Rich successfully to isolate Biosimilar productrelated impurities for industrial customers, satisfying requests from regulatory bodies including FDA



### The N-Rich<sup>®</sup> Process and its Applications



# N-Rich process using Contichrom<sup>®</sup> CUBE equipment



Contichrom runs multiple cycles automatically to enrich side compounds

- Avoid tedious collection of fractions from analytical runs
- N-Rich<sup>®</sup> single run to enrich side components or isoforms AND deplete undesired main component overnight
- Save weeks of tedious repetitive work when using analytical HPLC for preparative isolation tasks
- Preserve integrity of desired component through fast isolation



## How does the N-Rich process work?

• Process scheme: N-Rich consists of 3 sub-processes



The process operates with two identical columns packed with the same resin

#### **Discovery Applications: Conventional Fractionation**



#### **Discovery Applications: N-Rich Fractionation Automated**



# **N-Rich for Discovery Applications**

#### Automated Proteome screening with N-Rich<sup>®</sup>



Ċ

#### Example: Fractionation of a proteome

• The fractionation of intact proteins of a proteome is necessary because it results in an increased likeliness of detection of proteins of low abundance



#### Example: Fractionation of a proteome

#### **ASSUMPTIONS:**

- A: 5'000 proteins in the mixture yielding 40'000 tryptic fragments
- B: the average  $M_w$  of the proteins is 30 kDa
- C: at least 15 fmol are needed to obtain a peptide sequence by MS/MS
- This means 450 pg of each protein x 5000 proteins = 2.25  $\mu$ g of total protein needed
- Unfortunately proteins differ by 10<sup>6</sup> in relative abundance and a few proteins dominate the sample. Therefore in order to get 15 fmol of the least abundant protein you need to have at least 10<sup>5</sup> more sample
- 2.25  $\mu$ g x 10<sup>5</sup> = **225 mg TOTAL PROTEIN NEEDED**
- This means that you need to collect and process 500+ fractions with a strong cation exchanger (SCX) step using analytical HPLC
- With N-Rich the same task can be achieved in a much shorter time!

Ref: Andrew J Alpert PolyLC Inc.



#### Hardware and Software



#### The Contichrom<sup>®</sup> CUBE Combined FPLC/ and HPLC System

**Specifications:** 

CUBE/HPLC 30: 0.1-36 mL/min CUBE/HPLC 100: 0.1-100 mL/min UV-LED Detectors at 280 & 300 nm, optional 260 nm, optional variable wavelength detectors 190-500 nm Pressure rating: 50 bar (FPLC) 100 bar (HPLC)



#### Cooling the feed and the fractions during operations



#### N-Rich Wizard: Process design in 4 easy steps





#### Case Study: N-Rich for isolation of a synthetic peptide impurity



#### Case Study: Product-Related Impurity Isolation

 Fibrinopeptide A: Analytical injection 100 µL of Feed (3.0 g/L Fibrinopeptide) onto preparative RP-HPLC column





## Case Study: Product-Related Impurity Isolation

• Overlay of chromatogram of final gradient elutions (1min/ fraction)



- Blue: feed
- Pink, red, green: product related impurities isolated with N-Rich

## Case Study: Product-Related Impurity Isolation



\*with respect to main compound; \*\*not available, because purity is too low.

© ChromaCon 2016

#### Case study – Isolation of Biosimilar Antibody Isoforms



Case Study: Isolation of biosimilar mAb isoforms

- Industrial customer project: regulatory authority request for preclinical biosimilar impurity characterization
- Produce > 1 mg of 9 isoforms of a biosimilar mAb with > 90% purity



© ChromaCon 2016

Isoform	in Feed		
	[%]		
A1	1.5%		
A2	2.5%		
A3	1.5%		
A4	5.0%		
A5	8.5%		
КО	56.0%		
K1	14.5%		
P2	1.5%		
K2	3.5%		

Analytical IEX chromatogram

#### Case Study: Isolation of biosimilar mAb isoforms

## Workflow for isoform isolation





## Case Study: Isolation of biosimilar mAb isoforms (cont'd)



#### Left region for enrichment

**Step 1:** run a preparative CUBE FPLC run with a CIEX resin to identify early (left) and late (right) eluting isoforms)





**Step 2:** Upload the preparative batch from Step 1 and convert to N-Rich process in a guided way using the N-Rich wizard. Then execute pH gradient elution using a small particle CIEX resin.

The left region for enrichment chosen  $\rightarrow$  corresponds to weakly adsorbing acidic isoforms



**Step 3 (automatic):** Run N-Rich process for isolation of acidic isoforms overnight. Cycle overlay shows automated accumulation and enrichment of acidic isoforms P



![](_page_26_Figure_3.jpeg)

Accumulation Increase concentration of P, absolute and relative to W and S.

![](_page_26_Picture_5.jpeg)

**Step 4 (automatic):** The residual interfering component W is depleted. In this phase no feed is added. The objective of this step is to get the accumulated P components pre-purified

![](_page_27_Figure_2.jpeg)

![](_page_27_Figure_3.jpeg)

Separation Increase conc. of P, absolute and relative to W and S. Different gradient possible.

#### Total duration of sub-process: 3 h

![](_page_27_Picture_6.jpeg)

![](_page_28_Figure_0.jpeg)

© ChromaCon 2016

Case Study: Results of acidic isoform isolation using N-Rich

Isoforms A1 and A2 enriched and isolated

![](_page_29_Figure_2.jpeg)

**Step 2 repeated for basic isoforms:** Upload the preparative batch from Step 1 and convert to N-Rich process in a guided way using the N-Rich wizard. Then execute pH gradient elution using a small particle CIEX resin.

Theright region for enrichment chosen  $\rightarrow$  corresponds to weakly adsorbing basic isoforms

![](_page_30_Figure_3.jpeg)

**Step 3 repeated for basic isoforms (automatic):** Run N-Rich process for isolation of basic isoforms overnight. Cycle overlay shows automated accumulation and enrichment of basic isoforms P

![](_page_31_Figure_2.jpeg)

![](_page_31_Figure_3.jpeg)

Accumulation Increase concentration of P, absolute and relative to W and S.

![](_page_31_Picture_5.jpeg)

**Step 5 repeated for basic isoforms (automatic):** The pre-purified, accumulated component is further purified using a flat gradient obtaining the purified basic isoforms

![](_page_32_Figure_2.jpeg)

**Elution** Final elution with shallow gradient and fine fractionation.

![](_page_32_Figure_4.jpeg)

Case Study: Results of basic isoform isolation using N-Rich

Isoforms K1 and K2 isolated

![](_page_33_Figure_2.jpeg)

#### Enrichment through N-Rich process

• Final results: 5 acidic, 3 basic isoforms and the main isoform were isolated.

Isoform	in Feed	in N-Rich product	mass produced	enrichment
	[%]	[%]	[mg]	(by N-Rich)
A1	1.5%	80%	> 1.5	53x
A2	2.5%	85%	> 4.0	32x
A3	1.5%	90%	> 1.5	69x
A4	5.0%	> 90%	> 7.0	18x
A5	8.5%	> 90%	> 3.0	10x
КО	56.0%	> 90%	> 6.0	2x
K1	14.5%	90%	> 8.0	6х
P2	1.5%	50%	> 1.0	29x
К2	3.5%	75%	> 8.0	21x

![](_page_34_Picture_3.jpeg)

#### Time savings through N-Rich process

- mAb isoform isolation example:
  - Single isoform to isolate
  - Target amount 10 mg
  - 2.5% content in feed
  - 50 mL resin

N-Rich can reduce:

- ✓ the time for isolating and analyzing mAb isoforms from 32 to 3 days
- ✓ the number of samples to analyze from
  >600 to 50

 $\rightarrow$  10x increase in efficiency

#### Assumptions

Target amount	[mg]	10
Average content of isoform in feed	[%]	2.5%
Protein concentration in Feed	[mg/mL]	5.0
time for sample analysis	[hrs]	1
Resin volume	[mL]	50

Isoform Isolation		Batch	N-Rich
yield	[%]	5%	15%
load (total protein)	[g/L]	5	10
batch run / cycle duration	[hrs]	3	3
Number of cycles (N-Rich)	[-]		6
time for final elution N-Rich	[h]		6
amount of isoform produced per run	[mg]	0.3	11.3
cycles / runs needed	[-]	32	1
time for isoform isolation	[hrs]	96	24

#### Analytics

fractions for run	[-]	20	50
time for run fraction analysis	[h]	20	50
time for sample handling per run	[h]	0.7	1.7

#### Summary

total time for isolation	[d]	32	3
thereof analytics time	[d]	27	2

![](_page_35_Picture_17.jpeg)

#### Summary

- Isolation and analysis time of mAb isoforms could be reduced 10-fold through
  - N-Rich process
  - Reduced sample number / analytical burden
- mAb isoform isolation becomes a matter of days rather than weeks
- Using UPLC will lead to further reduction in overall time

![](_page_36_Figure_6.jpeg)

![](_page_36_Picture_7.jpeg)

![](_page_36_Picture_8.jpeg)

#### **Contact Information**

![](_page_37_Figure_1.jpeg)